Alpha 2.0
Login Register
» Articles » PMID: 23033160

An Evidence Base for Noradrenergic Deficits in Parkinson's Disease

Overview
Journal Mov Disord
Date 2012 Oct 4
PMID 23033160
Citations 4
Authors
Glenda Halliday
Affiliations
Soon will be listed here.
Citing Articles

Modulating arousal to overcome gait impairments in Parkinson's disease: how the noradrenergic system may act as a double-edged sword.

Tosserams A, Bloem B, Ehgoetz Martens K, Helmich R, Kessels R, Shine J Transl Neurodegener. 2023; 12(1):15.

PMID: 36967402 PMC: 10040128. DOI: 10.1186/s40035-023-00347-z.

Predictive model of spread of Parkinson's pathology using network diffusion.

Pandya S, Zeighami Y, Freeze B, Dadar M, Collins D, Dagher A Neuroimage. 2019; 192:178-194.

PMID: 30851444 PMC: 7180066. DOI: 10.1016/j.neuroimage.2019.03.001.

Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis.

Ermine C, Wright J, Frausin S, Kauhausen J, Parish C, Stanic D Hippocampus. 2018; 28(5):327-337.

PMID: 29431270 PMC: 5969306. DOI: 10.1002/hipo.22835.

Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.

Cao L, Peng X, Huang Y, Wang B, Zhou F, Cheng R Neural Plast. 2016; 2016:6383240.

PMID: 27747105 PMC: 5056271. DOI: 10.1155/2016/6383240.